These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2091796)

  • 1. Heparin and protamine therapy.
    Arén C
    Semin Thorac Cardiovasc Surg; 1990 Oct; 2(4):364-72. PubMed ID: 2091796
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
    Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative hemostasis.
    Ellison N; Campbell FW; Jobes DR
    Semin Thorac Cardiovasc Surg; 1991 Jan; 3(1):33-8. PubMed ID: 2015316
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized, controlled trial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass.
    Gruenwald CE; Manlhiot C; Chan AK; Crawford-Lean L; Foreman C; Holtby HM; Van Arsdell GS; Richards R; Moriarty H; McCrindle BW
    J Am Coll Cardiol; 2010 Nov; 56(22):1794-802. PubMed ID: 21087706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Control of temporary anticoagulation in extracorporeal circulation using activated coagulation time].
    Kessler G; Grünes G
    Anaesthesist; 1984 Dec; 33(12):588-91. PubMed ID: 6528961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety issues in heparin and protamine administration for extracorporeal circulation.
    Jobes DR
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two protocols for heparin neutralization by protamine after cardiopulmonary bypass.
    Arén C; Feddersen K; Rådegran K
    J Thorac Cardiovasc Surg; 1987 Oct; 94(4):539-41. PubMed ID: 3309479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of postoperative heparin rebound following cardiopulmonary bypass.
    Pifarré R; Babka R; Sullivan HJ; Montoya A; Bakhos M; El-Etr A
    J Thorac Cardiovasc Surg; 1981 Mar; 81(3):378-81. PubMed ID: 7464201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated clotting time for control of anticoagulation during surgery.
    Lefemine AA; Lewis M
    Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
    Teoh KH; Young E; Blackall MH; Roberts RS; Hirsh J
    J Thorac Cardiovasc Surg; 2004 Aug; 128(2):211-9. PubMed ID: 15282457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of patients at risk for protamine reactions.
    Levy JH; Schwieger IM; Zaidan JR; Faraj BA; Weintraub WS
    J Thorac Cardiovasc Surg; 1989 Aug; 98(2):200-4. PubMed ID: 2755152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass.
    Tuman KJ; Spiess BD; McCarthy RJ; Ivankovich AD
    Anesth Analg; 1989 Jul; 69(1):69-75. PubMed ID: 2742171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention.
    Patel AA; White CM; Coleman CI
    Conn Med; 2007 Feb; 71(2):93-5. PubMed ID: 17393902
    [No Abstract]   [Full Text] [Related]  

  • 17. Administration of protamine rather than heparin in a patient undergoing normothermic cardiopulmonary bypass.
    Metz S
    Anesthesiology; 1994 Mar; 80(3):691-4. PubMed ID: 8141468
    [No Abstract]   [Full Text] [Related]  

  • 18. [Measurement of activated clotting time during cardiopulmonary bypass in infective endocarditis patients].
    Jiang L; Yu JF
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):167-9. PubMed ID: 17344611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problems in hemostasis during open heart urgery. VII. Changes in fibrinogen concentration during and after cardiopulmonary bypass with particular reference to the effect of heparin neutralization on fibrinogen.
    Gans H; Castaneda AR
    Ann Surg; 1967 Apr; 165(4):551-6. PubMed ID: 6021455
    [No Abstract]   [Full Text] [Related]  

  • 20. Control of heparin therapy in open-heart surgery.
    Jaberi M; Bell WR; Benson DW
    J Thorac Cardiovasc Surg; 1974 Jan; 67(1):133-41. PubMed ID: 4808908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.